A Study of LY3502970 in Healthy Overweight and Obese Participants

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Official Title
-----------------
A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970

Conditions
-----------------
Healthy, Obese

Intervention / Treatment
-----------------
* Drug: LY3502970


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants with stable body weight for at least one month prior to randomization. Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²) Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential Exclusion Criteria: Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY3502970 (Dose Level 1)<br>LY3502970 administered orally. | Drug: LY3502970<br>* Administered orally.<br>|
| Experimental: LY3502970 (Dose Level 2)<br>LY3502970 administered orally. | Drug: LY3502970<br>* Administered orally.<br>|
| Experimental: LY3502970 (Dose Level 3)<br>LY3502970 administered orally. | Drug: LY3502970<br>* Administered orally.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module | Predose up to 42 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 | PK: AUC of LY3502970 | Predose up to 29 days postdose | 
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | PK: Cmax of LY3502970 | Predose up to 29 days postdose | 
| PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 | PK: Tmax of LY3502970 | Predose up to 29 days postdose | 
| Pharmacodynamics (PD): Change From Baseline in Body Weight | PD: Change From Baseline in Body Weight | Predose through Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacokinetics, Safety and Tolerability, LY3502970